Bli medlem
Bli medlem

Du är här


MorphoSys AG: MorphoSys to Start Share Buy-Back Program

MorphoSys AG / MorphoSys to Start Share Buy-Back Program. Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
The Management Board of MorphoSys AG (FSE: MOR; Prime Standard Segment,
TecDAX; OTC: MPSYY) today announced the decision to repurchase own shares
over the stock market for a total purchase price of up to EUR 5.39 million
(excluding ancillary costs). The share buy-back will take place during the
time period from April 9, 2015 to April 17, 2015, and is based on the
authorization of the Annual General Meeting on May 23, 2014. On the basis of
the current share price (EUR 57.45; Xetra closing price as of April 7, 2015),
the total purchasing volume amounts to up to 93,820 shares or 0.36% of the
registered share capital of the Company.

The Company intends to use the shares for its long-term incentive programs for
its Executive Board and the Senior Management Group, but the shares can also
be used for all other legally permitted purposes stated in the authorization
of the Annual General Meeting of 2014.

The relevant conditions of the shareholders' resolution passed in the Annual
General Meeting 2014 on the authorization to acquire and to use its own
shares shall apply. The purchase price paid per share may not be more than
10% higher or 20% lower than the Company's share price determined by the
opening auction in the Xetra trading system on the day of trading.

The share buy-back is to be handled independently of and uninfluenced by the
Company through an appointed bank in compliance with the safe-harbor

MorphoSys will provide regular information on the progress of the share
buy-back program on the Company's

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 90 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Manager Corporate Communications&IR

Jessica Rush
Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404

Media Release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.